Evidence map›Paper›PMID 37129800›Full record

ArticleInternational journal of hematology2023

Clinical management of second-generation tyrosine kinase inhibitor therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase, focusing on age and dose effects.

Michihide Tokuhira, Yuta Kimura, Takayuki Tabayashi, Naoki Watanabe, Shun Tsuchiya, Tomoiku Takaku, Noriyoshi Iriyama, Eriko Sato, Tomonori Nakazato, Toru Mitsumori and 7 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 10 institutions in 1 country.

Michihide TokuhiraDepartment of Hematology, Japan Community Health Care Organization Saitama Medical Center, Saitama, 330-0074, Japan. m_tokuhira@icloud.com.ORCID http://orcid.org/0000-0003-3780-5331
Yuta KimuraDepartment of Hematology, Japan Community Health Care Organization Saitama Medical Center, Saitama, 330-0074, Japan.
Takayuki TabayashiDepartment of Hematology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan.
Naoki WatanabeDepartment of Hematology, Juntendo University School of Medicine, Tokyo, Japan.
Shun TsuchiyaDepartment of Hematology, Juntendo University School of Medicine, Tokyo, Japan.
Tomoiku TakakuDepartment of Hematology, Juntendo University School of Medicine, Tokyo, Japan.
Noriyoshi IriyamaDivision of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan.
Eriko SatoDepartment of Hematology, Juntendo University Nerima Hospital, Tokyo, Japan.
Tomonori NakazatoDepartment of Hematology, Yokohama Municipal Citizen's Hospital, Yokohama, Japan.
Toru MitsumoriDepartment of Hematology, Juntendo University Urayasu Hospital, Urayasu, Japan.
Maho IshikawaDepartment of Hemato-Oncology, International Medical Center, Saitama Medical University, Saitama, Japan.
Hiroyuki FujitaDepartment of Hematology, Saiseikai Yokohama Nanbu Hospital, Yokohama, Japan.
Masahiro KizakiDepartment of Hematology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan.
Miki AndoDepartment of Hematology, Juntendo University School of Medicine, Tokyo, Japan.
Yoshihiro HattaDivision of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan.
Eisaku IwanagaDepartment of Hematology and Infectious Diseases, Kumamoto University Hospital, Kumamoto, Japan.
Tatsuya KawaguchiDepartment of Hematology and Infectious Diseases, Kumamoto University Hospital, Kumamoto, Japan.
Juntendo University · JPSocial Insurance Saitama Chuo Hospital · JPNihon University · JPJuntendo University Nerima Hospital · JPJuntendo University Urayasu Hospital · JPKumamoto Health Science University · JPKumamoto University Hospital · JPSaiseikai Ibaraki Hospital · JPSaitama Medical University · JPYokohama Municipal Citizen's Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

ABL1-tyrosine kinase inhibitors (TKIs) are an established treatment choice for patients with chronic myeloid leukemia in the chronic phase (CML-CP). However, effects of TKI dose modification have not been well investigated. In this study, we retrospectively analyzed 178 patients with newly diagnosed CML-CP who were treated with dasatinib or nilotinib, focusing on age and dose effects. Efficacy as measured by cumulative major molecular response (MMR) and molecular response 4.5 rates did not differ significantly between the younger group and elderly group. Elderly patients who started nilotinib at a reduced dose had similar or better efficacy outcomes (including cumulative MMR and continuation ratios) than other groups, and elderly patients who started dasatinib at a reduced dose had the lowest MMR ratio and longest MMR duration. Effects of dose modification based on age and TKI selection can be attributed to flexible management of TKI therapy in real-world practice, but further studies are required to validate the findings of this study.

Indexed as

Leukemia, Myelogenous, Chronic, BCR-ABL PositiveTyrosine Kinase InhibitorsAgedDasatinibHumansProtein Kinase InhibitorsPyrimidinesRetrospective StudiesTreatment OutcomeDasatinibProtein Kinase InhibitorsPyrimidinesTyrosine Kinase InhibitorsChronic myeloid leukemiaDasatinibDoseElderlyNilotinibYounger

Identifiers

PMID37129800
OpenAlexW4367668795

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.